HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025
HUTCHMED (HCM) has announced upcoming presentations of new and updated data from several studies at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago. The presentations will feature research on compounds discovered by HUTCHMED, including savolitinib, fruquintinib, and surufatinib.
The presentations include both sponsored and investigator-initiated studies, covering various aspects of cancer treatment. Key highlights include the SAVANNAH study examining plasma clearance in NSCLC patients, multiple studies on fruquintinib in colorectal cancer treatment, and several investigations of surufatinib in different cancer types. The research spans clinical trials, mechanism studies, and combination therapies with other treatments.
HUTCHMED (HCM) ha annunciato la presentazione imminente di nuovi dati aggiornati da diversi studi al American Association of Cancer Research (AACR) Annual Meeting 2025 a Chicago. Le presentazioni includeranno ricerche su composti scoperti da HUTCHMED, tra cui savolitinib, fruquintinib e surufatinib.
Le presentazioni comprendono studi sia sponsorizzati che avviati da ricercatori indipendenti, coprendo diversi aspetti del trattamento del cancro. I punti salienti includono lo studio SAVANNAH che analizza la clearance plasmatica nei pazienti con NSCLC, numerosi studi su fruquintinib nel trattamento del cancro colorettale e diverse indagini su surufatinib in vari tipi di tumore. La ricerca abbraccia trial clinici, studi sui meccanismi d’azione e terapie combinate con altri trattamenti.
HUTCHMED (HCM) ha anunciado próximas presentaciones de datos nuevos y actualizados de varios estudios en la Reunión Anual 2025 de la Asociación Americana para la Investigación del Cáncer (AACR) en Chicago. Las presentaciones incluirán investigaciones sobre compuestos descubiertos por HUTCHMED, incluyendo savolitinib, fruquintinib y surufatinib.
Las presentaciones comprenden estudios patrocinados y otros iniciados por investigadores, abarcando diversos aspectos del tratamiento del cáncer. Los puntos destacados incluyen el estudio SAVANNAH que examina la depuración plasmática en pacientes con NSCLC, múltiples estudios sobre fruquintinib en el tratamiento del cáncer colorrectal y varias investigaciones sobre surufatinib en diferentes tipos de cáncer. La investigación abarca ensayos clínicos, estudios de mecanismos y terapias combinadas con otros tratamientos.
HUTCHMED (HCM)는 시카고에서 열리는 2025년 미국암연구학회(AACR) 연례회의에서 여러 연구의 새로운 데이터와 업데이트된 데이터를 발표할 예정이라고 발표했습니다. 발표 내용에는 savolitinib, fruquintinib, surufatinib 등 HUTCHMED가 발견한 화합물에 관한 연구가 포함됩니다.
발표는 후원 연구와 연구자가 주도하는 연구를 모두 포함하며, 암 치료의 다양한 측면을 다룹니다. 주요 내용으로는 NSCLC 환자의 혈장 제거율을 조사하는 SAVANNAH 연구, 대장암 치료에 관한 fruquintinib 관련 여러 연구, 그리고 다양한 암종에 대한 surufatinib 연구가 있습니다. 이 연구들은 임상 시험, 작용 기전 연구, 다른 치료법과의 병용 요법을 포함합니다.
HUTCHMED (HCM) a annoncé la présentation prochaine de nouvelles données mises à jour issues de plusieurs études lors du Congrès annuel 2025 de l'American Association for Cancer Research (AACR) à Chicago. Les présentations porteront sur des composés découverts par HUTCHMED, notamment savolitinib, fruquintinib et surufatinib.
Ces présentations incluent des études sponsorisées ainsi que des études initiées par des chercheurs, couvrant divers aspects du traitement du cancer. Parmi les points forts, on trouve l'étude SAVANNAH qui examine la clairance plasmatique chez des patients atteints de NSCLC, plusieurs études sur le fruquintinib dans le traitement du cancer colorectal, ainsi que plusieurs investigations sur le surufatinib dans différents types de cancers. Les recherches englobent des essais cliniques, des études mécanistiques et des thérapies combinées avec d'autres traitements.
HUTCHMED (HCM) hat angekündigt, dass auf dem Jahrestreffen 2025 der American Association of Cancer Research (AACR) in Chicago neue und aktualisierte Daten aus mehreren Studien präsentiert werden. Die Präsentationen umfassen Forschungen zu von HUTCHMED entdeckten Verbindungen, darunter savolitinib, fruquintinib und surufatinib.
Die Präsentationen beinhalten sowohl gesponserte als auch von Forschern initiierte Studien und decken verschiedene Aspekte der Krebsbehandlung ab. Zu den Highlights gehört die SAVANNAH-Studie, die die Plasmaclearance bei NSCLC-Patienten untersucht, mehrere Studien zu fruquintinib in der Behandlung von kolorektalem Krebs sowie verschiedene Untersuchungen zu surufatinib bei unterschiedlichen Krebsarten. Die Forschung umfasst klinische Studien, Wirkmechanismus-Untersuchungen und Kombinationstherapien mit anderen Behandlungen.
- Multiple clinical trials and studies across different cancer types showing pipeline progress
- Strong presence at major scientific conference with 12 presentations
- Diverse research portfolio covering both single-agent and combination therapies
- None.
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED including savolitinib, fruquintinib and surufatinib, which will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2025, taking place on April 25-30, 2025 in Chicago, Illinois.
Details of the presentations are as follows:
| Abstract title | Presenter / Lead author | Presentation details |
SPONSORED STUDIES | ||
| Targeting KEAP1/NRF2 signaling sensitizes KRAS-driven NSCLC to KRAS inhibitors | Xianwen Yang, HUTCHMED, Shanghai, China | 4450 Poster Session (PO.ET03.04) Tuesday, April 29, 2025 |
| SAVANNAH: Clearance of plasma EGFRm in patients with EGFRm MET-overexpressed (OverExp) and/or -amplified (Amp) NSCLC post-osimertinib (osi) treated with savolitinib (savo) + osi | Jonathan W. Riess, University of California, UC Davis Comprehensive Cancer Center, CA, US | LB416 Late-Breaking Poster Session (LBPO.CL04) Wednesday, April 30, 2025 |
| A phase I open-label positron-emission tomography study to determine brain exposure of [11C]savolitinib in healthy volunteers | Kowser Miah, AstraZeneca, Waltham, MA, US | 4353 Poster Session (PO.ET07.01) Tuesday, April 29, 2025 |
INVESTIGATOR-INITIATED STUDIES | ||
| A multi-cohort study of treatment regimens for metastatic colorectal cancer (mCRC): Subgroup analysis of sequential therapy between fruquintinib and regorafenib | Wangxia Lv, Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, China | CT085 Poster Session (PO.CT02.03) Monday, April 28, 2025 |
| Phase Ib/II study of fruquintinib (F) combined with capecitabine (C) as maintenance therapy (MT) for RAS/BRAF wild-type metastatic colorectal cancer (mCRC) after first-line treatment with cetuximab combined with chemotherapy | Lin Yang/ Kai Ou, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China | CT222 Poster Session (PO.CT02.02) Tuesday, April 29, 2025 |
| Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Results of a multicenter, phase II trial (TRAP) | Jingdong Zhang/ Qian Dong, Liaoning Cancer Hospital & Institute, Cancer Hospital of Dalian University of Technology, Shenyang, China | 6002 Poster Session (PO.CL08.03) Tuesday, April 29, 2025 |
| Efficacy and mechanism of radiotherapy combined with fruquintinib and tislelizumab in mCRC | Xianglin Yuan, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China | 1828 Poster Session (PO.ET08.02) Monday, April 28, 2025 |
| Prediction of surufatinib treatment outcome in advanced grade 3 neuroendocrine tumors (NET G3) patients | Jing Hao, Qilu Hospital of Shandong University, Jinan, China | CT084 Poster Session (PO.CT02.03) Monday, April 28, 2025 |
| Surufatinib and sintilimab in combination with capecitabine for previously treated metastatic small bowel adenocarcinoma or appendiceal carcinoma: A single-arm, single-center, phase Ib/II trial | Yanhong Deng/ Xiaoyu Xie, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China | CT033 Poster Session (PO.CT01.03) Monday, April 28, 2025 |
| GPR34-driven damage-response macrophages underlie therapeutic resistance to surufatinib | Song Gao, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China | 6818 Poster Session (PO.ET07.02) Wednesday, April 30, 2025 |
| Efficacy and mechanism of surufatinib combination with PD-1 monoclonal antibody and chemotherapy for the treatment of pancreatic cancer with liver metastasis in animal models | Guanghai Dai/ Ru Jia, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China | 6824 Poster Session (PO.ET07.02) Wednesday, April 30, 2025 |
| Efficacy and mechanistic insights of Shengyang Qushi Decoction in managing surufatinib-associated diarrhea | Huangying Tan, China-Japan Friendship Hospital, Beijing, China | 1043 Poster Session (PO.PR02.03) Sunday, April 27, 2025 |
About Lung Cancer
Lung cancer is the leading cause of cancer death, accounting for about one-fifth of all cancer deaths.1 More than a third of the world’s lung cancer patients are in China. Lung cancer is broadly split into non-small cell lung cancer (“NSCLC”) and small cell lung cancer, with NSCLC accounting for about
About Savolitinib and MET Aberrations in Lung Cancer
Savolitinib is an oral, potent, and highly selective MET tyrosine kinase inhibitor (“TKI”) being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca. MET is a tyrosine kinase receptor that has an essential role in normal cell development.8 Savolitinib blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. MET overexpression and/or amplification can lead to tumor growth and the metastatic progression of cancer cells, and is a known mechanism of acquired resistance to EGFR TKIs.8,9 The prevalence of MET depends on the sample type, detection method and assay cut-off used.
Savolitinib is approved in China and is marketed under the brand name ORPATHYS® by AstraZeneca for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration, representing the first selective MET inhibitor approved in China. It is currently under clinical development for multiple tumor types, including lung, kidney, and gastric cancers as a single treatment and in combination with other medicines.
About Savolitinib in combination with TAGRISSO® (osimertinib)
Among patients who experience disease progression following treatment with a third-generation EGFR TKI, approximately 15
This combination represents a promising chemo-free oral treatment strategy to address mechanisms of resistance in this advanced setting. Positive data from the SACHI randomized Phase III trial has led to the filing of a second New Drug Application (“NDA”) in China. Strong data from the SAVANNAH single-arm Phase II study was recently presented at the European Lung Cancer Congress (ELCC) in March 2025 demonstrated high, clinically meaningful and durable objective response rate (ORR), with consistent safety results. The SAFFRON randomized Phase III trial is progressing. Following AstraZeneca’s consultation with the US Food and Drug Administration (“FDA”), we look forward to completing the SAFFRON trial as soon as possible to support potential US and other global registration filings.
SACHI: The SACHI China Phase III trial met the primary endpoint of progression free survival (PFS) during its interim analysis towards the end of 2024 and a NDA was accepted and granted Breakthrough Therapy Designation and Priority Review status in China in December 2024. SACHI evaluated the combination of savolitinib and TAGRISSO® for the treatment of patients with EGFRm, MET-amplified locally advanced or metastatic NSCLC after progression on EGFR TKI compared to platinum-based doublet chemotherapy. Results will be presented at an upcoming scientific conference.
SAFFRON: In 2023, savolitinib and TAGRISSO® received Fast Track Designation from the US FDA in this setting. The global SAFFRON Phase III trial is currently ongoing to assess the savolitinib plus TAGRISSO® combination versus platinum-based doublet chemotherapy in patients with EGFRm, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC following progression on treatment with TAGRISSO®. Patients are being prospectively selected using the high MET level cut-off identified in SAVANNAH.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of fruquintinib, savolitinib and surufatinib, the further clinical development for fruquintinib, savolitinib and surufatinib, its expectations as to whether any studies on fruquintinib, savolitinib and surufatinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fruquintinib, savolitinib and surufatinib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of fruquintinib, savolitinib and surufatinib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of osimertinib, capecitabine, sintilimab or tislelizumab, as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Medical Information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
CONTACTS
| Investor Enquiries | +852 2121 8200 / ir@hutch-med.com |
| Media Enquiries | |
| FTI Consulting – | +44 20 3727 1030 / HUTCHMED@fticonsulting.com |
| Ben Atwell / Alex Shaw | +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
| Panmure Liberum | Nominated Advisor and Joint Broker |
| Atholl Tweedie / Freddy Crossley / Rupert Dearden | +44 20 7886 2500 |
| HSBC | Joint Broker |
| Simon Alexander / Alina Vaskina / Arnav Kapoor | +44 20 7991 8888 |
| Cavendish | Joint Broker |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
________________________
REFERENCES
| 1 | World Health Organization. International Agency for Research on Cancer. All cancers fact sheet. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/39-all-cancers-fact-sheet.pdf. Accessed November 2022. |
| 2 | American Cancer Society. What is Lung Cancer? Available at: https://www.cancer.org/cancer/types/lung-cancer/about/what-is.html. Accessed November 2022. |
| 3 | Knight SB, et al. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7(9): 170070. DOI: 10.1098/RSOB.170070. |
| 4 | Keedy VL, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2011:29;2121-27. DOI: 10.1200/JCO.2010.31.8923. |
| 5 | Zhang Y, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48). DOI: 10.18632/oncotarget.12587. |
| 6 | Szumera-Ciećkiewicz A, et al. EGFR Mutation Testing on Cytological and Histological Samples in 11. Non-Small Cell Lung Cancer: a Polish, Single Institution Study and Systematic Review of European Incidence. Int J Clin Exp Pathol. 2013:6;2800-12. PMID: 24294366. |
| 7 | Vuong HG, et al. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysis. Lung Cancer. 2018; 123: 76-82. DOI: 10.1016/j.lungcan.2018.07.006. |
| 8 | Uchikawa E, et al. Structural basis of the activation of c-MET receptor. Nat Commun. 2021;12(4074). DOI: 10.1038/s41467-021-24367-3. |
| 9 | Wang Q, et al. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. Journal of Hematology & Oncology. 2019;63. DOI: 10.1186/s13045-019-0759-9. |
FAQ
What are the key compounds being presented by HUTCHMED (HCM) at AACR 2025?
What is the SAVANNAH study presenting about savolitinib at AACR 2025?
How many colorectal cancer studies involving fruquintinib will be presented at AACR 2025?
What types of surufatinib combination studies will be presented at AACR 2025?
